🔎 Trials Near Me

Home › Diffuse Scleroderma › California › Los Angeles

Pag-aaral pangklinika para sa Diffuse Scleroderma sa Los Angeles, CA

6 pag-aaral para sa Diffuse Scleroderma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Los Angeles (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.

Opisyal na teksto ng pag-aaral (English)

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Nagre-recruitPhase 2
  • UCLA, Los Angeles
Edad 18 hanggang 70 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06470048

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Nagre-recruitPhase 2
  • University of California Los Angeles Scleroderma Center, Los Angeles
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07287670

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

Nagre-recruitPhase 2/3
  • GSK Investigational Site, Los Angeles
  • GSK Investigational Site, Los Angeles
  • GSK Investigational Site, Los Angeles
Edad 18 pataas · Lahat ng kasarian · Na-update Set 8, 2026 · NCT05878717

Platform Clinical Study for Conquering Scleroderma

Nagre-recruitPhase 2
  • Keck School of Medicine at USC Medical Center, Los Angeles
  • Cedars-Sinai Medical Center, Los Angeles
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 18, 2026 · NCT06195072

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Nagre-recruitPhase 2
  • Artiva Investigational Site Los Angeles, Los Angeles
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 31, 2026 · NCT06991114

Pag-aaral para sa Diffuse Scleroderma sa ibang lungsod

Iba pang pag-aaral sa Los Angeles

Mula sa ClinicalTrials.gov, na-kuha noong Set 29, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.